

OVERVIEW

- Focus on repurposing drugs for rare & infectious diseases
- Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
- Developing Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders
- Robust patent portfolio ([12 patents and patent applications](#))
- Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)
- Significantly undervalued compared to its peers

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine	Infectious Diseases (COVID-19)	Phase 3 (COVID-19)	FDA approved for Phase 3
Psilocybin	Methamphetamine Use Disorder	Phase 1	CTA with University of Wisconsin
Psilocybin (Oral Formulations)	Depression, Anxiety, etc.	Pre-clinical	Target FDA Approval
CBD	Liver Diseases (Autoimmune Hepatitis)	Filing IND	Plan for Phase 2

UPCOMING MILESTONES

- Q1-21** FDA Phase 3 COVID-19 interim results
- Q1-21** Initiate FDA Phase 2 study for CBD in AIH
- Q1-21** Submit FDA IND Psilocybin (oral formulation)
- Q1-21** Start Phase 1 study – Psilocybin in Meth Disorder
- Q1-21** FDA Phase 3 COVID-19 interim results
- Q1-21** FDA Pre-IND – Bucillamine for infectious diseases
- Q2-21** Complete FDA Phase 3 study COVID-19

STRATEGIC PARTNERS

<p>Infectious Diseases CRO</p>	<p>Acquired March 2020 Psychedelic pharma</p>	<p>R&D partnership Psychedelic pharma</p>
<p>License of cannabidiol for treatment of Autoimmune Hepatitis</p>	<p>License of cannabinoid delivery technology</p>	<p>Psilocybin Collaboration</p>

TEAM

Management

Michael Frank (Chairman & CEO)
Carmelo Marrelli (CFO)
Derrick Welch (Founder, Psilocin Pharma)


Scientific and Clinical

Dr. Kelly McKee (CSO)
Dr. Osnesmo Mpanju (Regulatory)
Dr. John Fahy, MD (Clinical and Scientific Advisor)
Dr. Joel Moody, MD (Medical and Clinical Advisor)

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

VALUATION COMPARISON



STOCK INFORMATION

Ticker:	CSE: RVV, OTC: RVVTF
Share Price:	\$0.60 (Jan 8, 2021)
52-week High / Low:	CAD \$0.92 / \$0.035
Shares Outstanding:	259,219,666
Market Cap:	CAD ~ \$155,000,000